Related references
Note: Only part of the references are listed.The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras
Chadi Nabhan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Patterns of Delivery of Chemoimmunotherapy to Patients With Follicular Lymphoma in the United States: Results of the National LymphoCare Study
Peter Martin et al.
CANCER (2013)
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
Carsten Mueller et al.
BLOOD (2012)
Analysis of very elderly (>= 80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome
Chadi Nabhan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
Ulrich Jaeger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
Thomas E. Witzig et al.
LEUKEMIA & LYMPHOMA (2011)
How I treat elderly patients with diffuse large B-cell lymphoma
Michael Pfreundschuh
BLOOD (2010)
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2(+) Breast Cancer: A Survey of Oncologists
Arti Hurria et al.
ONCOLOGIST (2009)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
How I treat patients with diffuse large B-cell lymphorna
James O. Armitage
BLOOD (2007)
Comprehensive geriatric assessment for older patients with cancer
Martine Extermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Management of elderly patients with hematological neoplasms
O. Mora et al.
ANNALS OF ONCOLOGY (2007)
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Christian Buske et al.
BLOOD (2006)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Improved survival of follicular lymphoma patients in the United States
WT Swenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Share Paper
